Protecting Access to Diabetes Supplies Act of 2016
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Protecting Access to Diabetes Supplies Act of 2016 This bill amends title XVIII (Medicare) of the Social Security Act to modify provisions relating to Medicare's competitive acquisition program (through which rates are set through a competitive bidding program rather than by an established fee schedule) with respect to diabetic testing strips. Specifically, the bill requires the Centers for Medicare & Medicaid Services (CMS) to: use specified data to determine whether a bid satisfies certain requirements related to volume of coverage with respect to such products, reject a bid if the bidder does not demonstrate its ability to furnish such products in a manner consistent with its bid, and establish a process to monitor the extent to which an entity continues to cover the product types included in its bid. CMS may terminate a contract if it determines that an entity, for reasons other than product discontinuation or market-wide shortage, fails to maintain ready access to such products included its bid. In addition, the bill specifies that an entity furnishing such products to beneficiaries under the program: (1) must furnish to each beneficiary a brand of strips that is compatible with the beneficiary's home blood glucose monitor, (2) may not attempt to influence or incentivize a beneficiary to switch the brand of either type of product, and (3) must contact and receive a request from a beneficiary no more than 14 days prior to dispensing a refill to the beneficiary.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (1)
2017 · second_quarter · Pharmacy
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Client expense: $130,000 · Firm income: Not reported
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · second_quarter · Medicare/Medicaid
H. R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Client expense: $130,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · second_quarter · Health Issues
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015. H.R. xxxx - Regulatory framework for in-vitro clinical tests (unnamed discussion draft, and Diagnostic Accuracy and Innovation Act).
Client expense: $130,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · first_quarter · Medicare/Medicaid
H. R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Client expense: $145,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Health Issues
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015. H.R. xxxx - Regulatory framework for in-vitro clinical tests (unnamed discussion draft, and Diagnostic Accuracy and Innovation Act).
Client expense: $145,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2017 · first_quarter · Pharmacy
H.R. 771 and S.4 - Protecting Access to Diabetic Testing Supplies Act of 2015.
Client expense: $145,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medicare/Medicaid
HR 771: Protecting Access to Diabetic Testing Supplies Act of 2015. S.4 - Protecting Access to Diabetes Supplies Act of 2016. Legislation affecting Medicare payments for laboratory services. WHO PQ Process for Diagnostics. Develop streamlined process to get QW modifier added to tests that are granted CLIA-waived status by the FDA.
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE